Rohini Sharma, Anjana Pillai, Thomas Urban Marron, Petros Fessas, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, David Szafron, Abdul Rafeh Naqash, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Chieh‐Ju Lee, Pei‐Chang Lee, Anushi Bulumulle, Sonal Paul, Dominic Bettinger, Hannah Hildebrand, Mohammed Yehia, Tiziana Pressiani, Ahmed Kaseb, Yi‐Hsiang Huang, Celina Ang, Masatoshi Kudo, Naoshi Nishida, Nicola Personeni, Lorenza Rimassa, David James Pinato – 27 April 2022 – The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HC

Nupur Sharma, Manisha Yadav, Gaurav Tripathi, Babu Mathew, Vasundhra Bindal, Sanyam Falari, Viniyendra Pamecha, Jaswinder Singh Maras – 27 April 2022

Rujittika Mungmunpuntipantip, Viroj Wiwanitkit – 27 April 2022

Yoshihiro Kamada, Takashi Nakahara, Kensuke Munekage, Hideki Fujii, Yoshiyuki Sawai, Yoshinori Doi, Masafumi Ono, Hideyuki Hyogo, Yoshio Sumida, Koichi Morishita, Tatsuya Asuka, Tsunenori Ouchida, Yasuharu Imai, Eiji Miyoshi, Japan Study Group of NAFLD – 26 April 2022 – We previously demonstrated that Mac‐2 binding protein (M2BP) is a useful biomarker for nonalcoholic fatty liver disease (NAFLD), particularly NAFLD fibrosis prediction. In the present study, we investigated the prognostic value of M2BP in patients with NAFLD.

AASLD develops evidence-based practice guidelines and practice guidances which are updated regularly by a multi-disciplinary panel of experts, including hepatologists, and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. 

Manhal Izzy, Hilary M. DuBrock – 25 April 2022

Coralie Amadou, Oumarou Nabi, Lawrence Serfaty, Karine Lacombe, Jérôme Boursier, Philippe Mathurin, Céline Ribet, Victor Ledinghen, Marie Zins, Marie‐Aline Charles – 25 April 2022

Jorge Reyes, Evelyn Hsu – 25 April 2022

Stefano Ciardullo, Marco Carbone, Pietro Invernizzi, Gianluca Perseghin – 25 April 2022 – Recently, an expert panel proposed diagnostic criteria for metabolic dysfunction–associated fatty liver disease (MAFLD) in the pediatric population. The aim of this study was to evaluate the prevalence of MAFLD among US adolescents and to investigate whether the new MAFLD definition is able to identify individuals with more advanced liver disease.

Manhal Izzy, Hilary M. DuBrock – 25 April 2022